PharmaCyte Biotech, Inc. - May 23, 2024 Form 3 Insider Report for MyMD Pharmaceuticals, Inc. (MYMD)

Role
10%+ Owner
Signature
/s/ Carlos Trujillo, Chief Financial Officer
Stock symbol
MYMD
Transactions as of
May 23, 2024
Transactions value $
$0
Form type
3
Date filed
5/30/2024, 04:05 PM
Previous filing
Nov 28, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MYMD Series G Convertible Preferred Stock May 23, 2024 Common stock, par value $0.001 per share 3.85M $1.82 Direct F1
holding MYMD Warrants May 23, 2024 Common stock, par value $0.001 per share 3.85M $1.82 Direct
holding MYMD Warrants May 23, 2024 Common stock, par value $0.001 per share 3.85M $1.82 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series G Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date.